ZD1839 (Iressa)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ZD1839 (Iressa), covering 2020-06-02 to 2020-06-02. Get the full timeline:
Most recent: Clinical Trial Update: Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer [Phase 2]